Top 10 Pharmaceuticals markets in Saudi ArabiaThe fastest-growing and largest of the 20 sized Pharmaceuticals markets in Saudi Arabia, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $627 Mn | $6.5 Bn | 26.4% | 2 |
| 2 | Cell Based Immunotherapy | $282 Mn | $2.5 Bn | 24.5% | 71 |
| 3 | Cannabidiol (CBD) | $375 Mn | $2 Bn | 18.3% | 0 |
| 4 | Cannabis | $576 Mn | $2.3 Bn | 15% | 0 |
| 5 | Atopic Dermatitis Drugs | $191 Mn | $689 Mn | 13.7% | 5 |
| 6 | Oncology/Cancer Drugs | $3 Bn | $7.7 Bn | 9.9% | 53 |
| 7 | Anti-Aging | $1.5 Bn | $3.7 Bn | 9.6% | 1 |
| 8 | Diabetes Management | $1.3 Bn | $3 Bn | 8.6% | 17 |
| 9 | Alzheimer Drugs | $85 Mn | $189 Mn | 8.3% | 2 |
| 10 | Contraceptives Drugs | $428 Mn | $951 Mn | 8.3% | 0 |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $3 Bn | $7.7 Bn | 9.9% | 53 |
| 2 | Anti-Aging | $1.5 Bn | $3.7 Bn | 9.6% | 1 |
| 3 | Diabetes Management | $1.3 Bn | $3 Bn | 8.6% | 17 |
| 4 | Gastrointestinal Drugs | $918 Mn | $1.7 Bn | 6.1% | 17 |
| 5 | Asthma & COPD Drugs | $842 Mn | $1.4 Bn | 5.5% | 8 |
| 6 | Biosimilars | $627 Mn | $6.5 Bn | 26.4% | 2 |
| 7 | Cannabis | $576 Mn | $2.3 Bn | 15% | 0 |
| 8 | HIV Drugs | $510 Mn | $1 Bn | 7.3% | 0 |
| 9 | Contraceptives Drugs | $428 Mn | $951 Mn | 8.3% | 0 |
| 10 | Cancer Supportive Care Drugs | $422 Mn | $769 Mn | 6.2% | 10 |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 26.4% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (24.5%).
Oncology/Cancer Drugs is the largest, worth about $3 Bn in 2023 and $7.7 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.
UAE